skip to Main Content

Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Researchers examined how neoadjuvant therapy affects the survival of patients with borderline-resectable pancreatic ductal adenocarcinoma (PDAC).

The National Cancer Database yielded data of 7,730 patients with resectable PDAC and 1,980 patients with borderline-resectable PDAC from 2004 to 2015. Patients with resectable PDAC and patients with borderline-resectable disease treated with neoadjuvant therapy showed similar median overall survival (mOS) (26.5 vs 25.7 months). Read more . . .


Back To Top